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The term ‘syndemic’ describes linked health problems involving two or more 
conditions that act synergistically, causing an excess burden of disease in the 
population. These interacting conditions often cluster similarly by person, 
place, and time.  Most importantly, interventions against them must address the 
underlying conditions that bind the problems together1. The global incidence 
of tuberculosis (TB) has declined over the last few decades, albeit far slower 
than envisioned by the World Health Organization (WHO).  For 2018–2019, 
TB incidence only declined by 2.3%, suggesting that WHO objectives for 2030 
will not be met2. Ten million persons were infected in 2019, but the burden of 
TB disease is highest in low- and middle-income countries (LMICs), where 95% 
of TB deaths occur. The high TB burden countries include India, Indonesia, 
China, Philippines, and Bangladesh, and these nations also rank among the top 
ten countries for daily smoking prevalence3. Poverty, poor nutrition, and lack of 
comprehensive healthcare systems in these nations play into the TB and smoking 
syndemic. 
Smoking and secondhand smoke exposure are two of several conditions that 
exacerbate adverse TB outcomes such as recurrent disease, excess mortality, and 
treatment failure.  These conditions include diabetes, poor nutrition, alcohol use, 
and HIV infection. Because there are over one billion smokers globally, it is 
not surprising that 17.6% (95% CI: 8.4–21.4) of new cases and 15.2% (95% CI: 
1.8–31.9) of TB deaths are attributable to smoking in high burden countries, 
regardless of other risk factors4.  
Given the syndemicity of TB and tobacco use, we might ask what would happen 
if the smoking prevalence among those infected with TB could be effectively 
reduced through consistent, integrated treatment for tobacco use. Unfortunately, 
and despite a higher prevalence of smoking in TB patients compared to the 
general population5, the vast majority of TB patients are neither routinely asked 
about their smoking status nor advised to quit6.
Some progress has been made to meet the syndemic challenge of TB and 
smoking. There has been increased interest in policies to help TB patients quit 
smoking7 as well as recognition of the need for evidence-based smoking cessation 
interventions8. The WHO and the Union were first to embrace this challenge in the 
2007 Monograph on TB and Tobacco Control, which called for further research and 
the application of cessation assistance in TB programs9. There are also a few large 
randomized-controlled trials (RCTs)8,10 conducted in high-TB burden countries, 
which highlight that face-to-face behavioral interventions can achieve high quit 
rates among TB patients8. Those who quit smoking were shown to have better 
overall clinical outcomes. In these studies, TB staff were able to deliver behavioral 
interventions for smoking cessation. However, because of several health system 
barriers11  (e.g. cost, reach, sustainability), no high-TB burden country has so far 
integrated consistent face-to-face behavioral interventions for smoking cessation 
within its TB services. Recognizing the challenges of integrating and scaling 
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up face-to-face interventions, WHO has developed 
a smoking cessation package (mTB-Tobacco) that 
can be delivered as mobile phone messages to TB 
patients12. 
The evidence so far points towards a strong 
syndemic association between adverse TB outcomes 
and tobacco use. The evidence is also emerging in 
support of face-to-face behavioral interventions that 
can be delivered within health services in high-TB 
burden countries. On the upcoming World TB Day, 
we want to emphasize the important contribution of 
tobacco use in sustaining the TB disease burden and 
to appeal to policymakers and practitioners in high-
TB burden countries that they recognize tobacco 
cessation as an important part of our efforts to end 
the global TB epidemic.
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